This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ObjectiveClinical practice currently faces a significant shortfall in specific biomarkers needed for diagnosing right ventricular (RV) remodeling in patients with pulmonary hypertension (PH). MiRNA sequencing analyses revealed 19 dif-miRNAs (12 upregulated and 7 downregulated) between the two groups.
Specific cardiovascular diseases, such as acute myocardial infarction, arrhythmias, pulmonary hypertension and pericarditis, were also pointed. Further studies are needed to identify specific/distinctive biomarkers to improve early detection of CVDs in silica exposed workers.
This results in severe chest pain or discomfort, with the subsequent release of cardiac biomarkers, and alterations in the electrocardiogram. Hypertension and diabetes were the two most common risk factors identified. It can cause diminished heart function and mortality if not treated properly with suitable measures.
Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH). For years, Dr. Zanos has investigated bioelectronic medicine therapies to treat PAH.
“This latest patent further secures the broad therapeutic potential of brilaroxazine for inflammatory conditions driven by underlying disruption in serotonin signaling like pulmonary hypertension,” said Laxminarayan Bhat, Ph.D. Founder, President, and CEO. Brilaroxazine has already received Orphan Drug Designation by the U.S.
Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
Hypertension, Ahead of Print. BACKGROUND:The mediating role of inflammatory biomarkers in the causal relationship between body composition and hypertension remains unclear and requires further investigation.METHODS:This study used a combination of retrospective observational analysis and Mendelian randomization approaches.
Introduction Pre-hypertension is a prevalent condition among the adult population worldwide. It is characterized by asymptomatic elevations in blood pressure beyond normal levels but not yet reaching the threshold for hypertension. Objective The precise mechanisms driving the progression of hypertension remain unknown.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a complex pulmonary vascular disorder that involves major vessel and microvascular disease components. 1 2 Secondary microvasculopathy of CTEPH forms the pathophysiological basis for pulmonary hypertension-targeted medical therapies given for CTEPH.
For example, blood pressure changes during exercise (EBP) can reveal a latent tendency toward future development of hypertension. At present, there is no reliable circulating biomarker—a protein or other molecule present in the blood stream—indicative of hypertension risk.
Hypertension, Ahead of Print. Hypertension-associated cerebral small vessel disease is a common finding in older people. Strongly associated with age and hypertension, small vessel disease is found at autopsy in over 50% of people aged ≥65 years, with a spectrum of clinical manifestations.
Background:Acquired mitochondrial dysfunction is one of the characteristics of pulmonary arterial hypertension (PAH). Exploring potential biomarkers from mitochondrial perspective may be effective in the diagnosis and treatment of PAH. Molecular docking and drug prediction showed estradiol is a potential targeted drug for ARMCX3.
This study aimed to evaluate the association of triglyceride-glucose (TyG) index, an insulin resistance surrogate biomarker, with first stroke in a hypertensive population and to explore potential influencing.
This study aims to identify risk factors for new-onset HDP and to develop a prediction model for assessing the risk of new-onset hypertension during pregnancy.MethodsWe included 446 pregnant women without baseline hypertension from Liyang People's Hospital at the first inspection, and they were followed up until delivery.
BackgroundChronic arterial hypertension restructures the vascular architecture of the brain, leading to a series of pathological responses that culminate in cerebral smallvessel disease. Journal of the American Heart Association, Ahead of Print. Microvessels were isolated for gene expression profiling and invitro pericyte expansion.
BackgroundThe relationship between human immunodeficiency virus (HIV) infection and pulmonary arterial hypertension (PAH) has garnered significant scrutiny. Individuals with HIV infection have a higher risk of developing PAH. However, the specific mechanism of HIV-associated PAH remains unclear.
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
Background:Distinguishing hypertrophic cardiomyopathy (HCM) from other cardiomyopathies with left ventricular hypertrophy (LVH), such as hypertensive LVH, transthyretin amyloid cardiomyopathy (ATTR-CM), and aortic stenosis (AS), is sometimes challenging. Of those, 5 proteins were selected as candidate proteins.
BACKGROUND:Pulmonary hypertension, characterized by vascular remodeling, currently lacks curative therapeutic options. The dysfunction of pulmonary artery endothelial cells plays a pivotal role in the initiation and progression of pulmonary hypertension (PH). Circulation, Ahead of Print.
Hypertension, Ahead of Print. Generalized estimating equations were used to estimate the associations of 233 plasma proteins with hypertension and systolic blood pressure (SBP). Validation in the KORA-Age1/Age2 study replicated 7 proteins associated with hypertension and 23 associated with SBP. years of follow-up.
Hemorrhagic strokes (HS) are increasingly significant causes of disability and mortality worldwide, making the use of blood biomarkers for their diagnosis and prognosis critical. Stroke, Volume 56, Issue Suppl_1 , Page AWP230-AWP230, February 1, 2025.
BACKGROUND:Exercise-induced hypertension (EIH) is common in adults with coarctation of the aorta (COA), but there are limited data about hemodynamics and outcomes in such patients. Circulation: Heart Failure, Ahead of Print.
Hypertension, Volume 80, Issue 12 , Page 2547-2555, December 1, 2023. BPV was evaluated by the SD, coefficient of variation, and average real variability of the patients’ 24-hour ambulatory and home systolic BP values.RESULTS:During the median 7.0-year year follow-up, 109 cardiovascular events occurred.
Hypertension, Ahead of Print. Hypertension is the primary modifiable risk factor for cardiovascular, renal, and cerebrovascular diseases and is considered the main contributing factor to morbidity and mortality worldwide.
There was no strong evidence of an interaction between urinary sodium and a standard genome-wide polygenic score of BP.CONCLUSIONS:The data suggest that genetic risk in sodium and potassium pathways could be used in a precision medicine model to direct interventions more specifically in the management of hypertension.
The triglyceride–glucose (TyG) index, proven to be a crucial insulin resistance biomarker (better than the Homeostasis Model Assessment for Insulin Resistance), is simple and non-invasive.
were women, 87% had hypertension, 48.1% It also identifies a novel biomarker for ischemic strokes from atherosclerosis. The relationship between stroke etiology (TOAST criteria) and IL-2Rα was assessed using ANOVA and then adjusted for co-morbidities using multilinear regression models.Results:The mean age of patients was 63.4
years, 54% were women, 87% had hypertension, 44% had diabetes mellitus, and 54% had hyperlipidemia. Only two out of the 48 cytokines demonstrated differences with thrombectomy. CCL4 levels were significantly higher in patients that underwent thrombectomy, 55.717.4 pg/ml vs. 39.520.6
Innovations in Cardiorenal Metabolic Medicine The event will focus on the whole spectrum of cardiorenal metabolic disease, including obesity, diabetes, lipids, hypertension, and cardiorenal disease. Michos, MD, MHS, FACC, FAHA, FASE, FASPC ; famed hypertension expert Keith C. Morris, MD as featured speakers; CMHC co-chairs Anne L.
CardioSignal has already developed digital biomarkers for AFib and heart failure, while more solutions could be on the way for aortic stenosis, coronary artery disease, and pulmonary artery hypertension.
BackgroundPulmonary artery hypertension (PAH) is a fatal disease characterized by a complex pathogenesis. Exosomes containing microRNAs (miRs) have emerged as a novel biomarker. Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023.
Hypertension, Ahead of Print. BACKGROUND:Renin-independent aldosterone production in normotensive people increases risk for developing hypertension. These findings provide mechanistic explanations to implicate PA in the pathogenesis of a substantial proportion of hypertension.
Participants underwent clinical cardiovascular evaluation, ECG, cardiac biomarker evaluation and CMR. 33% of participants had a new finding of hypertension. All participants had normal LVEF prior to, and on completion of, treatment. Left ventricular systolic dysfunction (LVSD) was defined as LVEF <50%. years (range 5.9–10.8
Hypertension, Ahead of Print. BACKGROUND:Preeclampsia is a hypertensive pregnancy disorder marked by endothelial damage. Sphingosine-1-phosphate (S1P) is a cardiovascular biomarker involved in glycocalyx preservation, linked to placentation and preeclampsia development.
The most common comorbidities were hyperlipidemia (93.3%) and hypertension (80%). Furthermore, these patients could benefit from early surgical intervention if these biomarkers were to be detected. There were 73.3% male patients. of patients had symptomatic disease. Eleven plaques were vulnerable in preoperative MRI with VWI.
Multiple metabolites of KP have been observed to exhibit elevated concentrations in plasma across various cardiovascular diseases, such as atherosclerosis, hypertension, and acute myocardial infarction. Multiple studies have indicated that kynurenine (KYN) may serve as a potential biomarker for several adverse cardiovascular events.
Arterial hypertension (HR 2.27; 95% CI 1.00 Arterial hypertension (HR 2.27; 95% CI 1.00 Kaplan-Maier estimators of the combined end point were 31% in patients with arterial hypertension, 56% in patients with severe valvular heart disease and 77% with both risk factors (HR 12.4, 95% CI 3.8
We aim to assess differences in the biomarkers among the phenotypes of HFpEF and investigate its multifactorial pathophysiology. Biomarker characteristics in each phenotype were evaluated. Conclusions Distinctive characteristics of biomarkers in HFpEF phenotypes would indicate differential underlying mechanisms to be elucidated.
Patients with increasing CT-CSVD scores were older (p<0.001), more likely to have hypertension (p<0.001), diabetes (p<0.001), coronary artery disease (p=0.044), and a higher baseline systolic blood pressure (p=0.037). 1.02; score 2: OR 0.46, 95%CI 0.26-0.83; 0.83; score 3: OR 0.16, 95%CI 0.03-0.76, 1.95, p = 0.019).Conclusion:This
Hypertension, Ahead of Print. BACKGROUND:Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension.
Hypertension, Ahead of Print. BACKGROUND:Circulating proteins in blood are involved in various physiological processes, but their contributions to blood pressure regulation remain partially understood.
By comparing myocardial injury patients with non-myocardial injury patients, notable differences were observed in age, pre-existing medical conditions (e.g.,
million, or 47% of adults are estimated to have hypertension.** percent of adults have high LDL-C (>/_ 130 mg/dL).** - The age-adjusted death rate attributable to CVD is 224.4 per 1,000* - 122.4 People with diabetes are twice as likely to have heart disease or a stroke than people without diabetes. -
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content